DrugPatentWatch Database Preview

Details for Patent: 9,114,068

« Back to Dashboard

Which drugs does patent 9,114,068 protect, and when does it expire?

Patent 9,114,068 protects CALDOLOR and is included in one NDA.

This patent has twenty-one patent family members in eight countries.

Summary for Patent: 9,114,068

Title:	Treating patients with intravenous ibuprofen
Abstract:	Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure.
Inventor(s):	Pavliv; Leo (Cary, NC), Rock; Amy Dix (Thompson Station, TN)
Assignee:	Cumberland Pharmaceuticals, Inc. (Nashville, TN)
Application Number:	14/264,267
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 9,114,068

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Cumberland Pharms	CALDOLOR	ibuprofen	SOLUTION;INTRAVENOUS	022348-002	Jun 11, 2009		RX	Yes	Yes						METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL

Non-Orange Book US Patents Family Members for Patent 9,114,068

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,138,404	Treating critically ill patients with intravenous ibuprofen
9,295,639	Treating critically ill patients with intravenous ibuprofen
8,735,452	Treating patients with intravenous ibuprofen
9,649,284	Treating critically ill patients with intravenous ibuprofen

International Patents Family Members for US Patent 9,114,068

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009350474
Australia	2010274030
Brazil	PI0925034
Canada	2766367